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AbstrAct
Capecitabine is commonly used in treating breast cancer; however, therapeutic 
response varies among patients and there is no clinically validated model to predict 
individual outcomes. Here, we investigated whether drug sensitivity quantified in 
ex vivo patients’ blood-derived cell lines can predict response to capecitabine in vivo. 
Lymphoblastoid cell lines (LCLs) were established from a cohort of metastatic breast 
cancer patients (n = 53) who were prospectively monitored during treatment with 
single agent capecitabine at 2000 mg/m2/day. LCLs were treated with increasing 
concentrations of 5’-DFUR, a major capecitabine metabolite, to assess patients’ ex vivo 
sensitivity to this drug. Subsequently, ex vivo phenotype was compared to observed 
patient disease response and drug induced-toxicities. We acquired an independent cohort 
of breast cancer cell lines and LCLs derived from the same donors from ATCC, compared 
their sensitivity to 5’-DFUR. As seen in the patient population, we observed large inter-
individual variability in response to 5’-DFUR treatment in patient-derived LCLs. Patients 
whose LCLs were more sensitive to 5’-DFUR had a significantly longer median progression 
free survival (9-month vs 6-month, log rank p-value = 0.017). In addition, this significant 
positive correlation for 5’-DFUR sensitivity was replicated in an independent cohort of 8 
breast cancer cell lines and LCLs derived from the same donor. Our data suggests that 
at least a portion of the individual sensitivity to capecitabine is shared between germline 
tissue and tumor tissue. It also supports the utility of patient-derived LCLs as a predictive 
model for capecitabine treatment efficacy in breast cancer patients. 
IntroductIon
Capecitabine is an oral fluopyrimidine prodrug 
commonly used in treating breast and colorectal cancer 
patients. It is metabolized to 5ʹ-deoxy-5-fluorouridine 
(5ʹ-DFUR), which is further converted into the active 
metabolite 5-fluorouracil (5-FU) in vivo [1, 2]. In breast 
cancer patients, capecitabine is approved for the treatment 
of taxane-resistant metastatic breast cancer either as 
monotherapy or in combination with other chemotherapeutic 
agents. As monotherapy, and in combination with other 
chemotherapies, clinical trials have shown that capecitabine 
treatment results in a median overall survival range from 
11–19 months and a median progression free survival (PFS) 
ranging from 3–9 months [3–6]. 
To maximize efficacy, studies have been conducted 
to identify patients who are likely to be non-responsive to 
capecitabine therapy prior to beginning a capecitabine-based 
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regimen. Genetic variants that result in enzyme (e.g. thymidine 
phosphorylase (TP) and dihydropyrimidine dehydrogenase 
(DYPD)) activity deficiencies have also been shown to 
independently predict toxicity and sensitivity to capecitabine 
[7, 8]. More recently, the role of germline genetic variants in 
capecitabine sensitivity has been explored using a human cell-
based model: the International HapMap lymphoblastoid cell 
lines (LCLs) [9].  
 Indeed, HapMap LCLs have previously been 
successfully used for pharmacogenomic discoveries of 
various drugs [10, 11]. Several genetic markers identified 
in this model have been validated in vivo in different cancer 
settings [9, 12]. However, HapMap LCLs were generated 
from apparently healthy donors with no known morbidities 
at the time of LCL establishment. Our study seeks direct 
answers to the question of whether establishing LCLs from 
diseased individuals is feasible and more importantly, 
how relevant/useful is a patient-derived LCL model in the 
clinical setting. In this study, we aimed at developing a 
blood-based ex vivo model for prediction of capecitabine 
sensitivity in breast cancer patients. Our rationale is 
that human peripheral blood is readily accessible and 
phenotypes obtained in this model can reflect both genetic 
and environmental effects on an individual. Specifically, 
we established LCLs from breast cancer patients and 
examined the relationship between phenotypes obtained 
in this ex vivo model and drug sensitivity phenotype 
(efficacy) obtained from the actual patients. Our hypothesis 
is that a patient-derived ex vivo LCL model can be used 
to predict a patient’s clinical response to capecitabine. 
Furthermore, the establishment of LCLs from patients 
will provide materials for subsequent functional studies of 
gene and/or other genetic/epigenetic components without 
repeated clinical sampling, thus benefiting additional 
scientific discovery and validation. 
results 
clinical response to capecitabine treatment 
53 patients were included in this study and their 
ages ranged from 36 to 79 with a median age of 51 years 
old. The majority of patients were White (71%), with 
17% African American and 1% Asian. Detailed clinical 
response/toxicity assessment results are shown in Table 
1. Both short term and long term clinical responses were 
collected. The short term response was measured at 10–
12 weeks capecitabine treatment; while the long term 
response was assessed using PFS, which range from 6 
weeks to 32 months. Site of enrollment did not have an 
effect on response to capecitabine (data not shown). 
establishment of breast cancer patient-derived lcls
Of the 53 patients who donated blood for our study, 
we successfully established LCLs for 45 individuals 
(success rate 85%). The reasons for failure to establish 
LCLs include improper method of blood storage/shipment 
(n = 4, blood received frozen and unable to isolate 
peripheral blood mononuclear cells (PBMCs)), shortage of 
EBV supplies from the vendor (n = 1), and failure to attain 
persistent proliferating status (n = 3).  To assess technical 
variability and to verify that the variability of drug 
response observed among LCLs is due to inter-patient 
heterogeneity rather than possible heterogeneity caused 
by the establishment process, patient PBMCs were split 
into 2 vials and 2 independent LCLs from each individual 
donor were developed.  The established LCLs were treated 
with increasing concentrations of 5ʹ-DFUR (0–160 μM) 
and cell proliferation was assessed using Cell Titer Glo 
reagent. We found that in the majority of patient samples, 
there was no significant difference between the 2 batches 
of LCLs and their response to 5ʹ-DFUR treatment (p-value 
> 0.05 from two-way ANOVA test between the drug 
sensitivity curves derived from each of the 2 batches of 
LCLs, Supplementary Figure 1). Thus, one LCL per patient 
was used for analysis. However, less than 8% of the patient 
derived LCLs (n = 4) showed variable 5ʹ-DFUR sensitivity 
(defined by >15% variability) in the 2 independent LCLs 
created from the same individual. Both batches from each 
of these patients were removed from further analysis. 
Capecitabine response in patient-derived LCLs were 
also grouped based on their site of enrollment, and using 
one-way ANOVA, we found that there was no significant 
difference in their response to 5ʹ-DFUR (p =  0.63).  
Patient-derived LCLs’ sensitivity to 5ʹ-DFUR
We observed that increasing concentrations of 
5ʹ-DFUR, correlated with a decrease in the cell viability 
of patient-derived LCLs (Supplementary Figure 2). 
Furthermore, large inter-individual variability e.g., 3-fold 
difference at 10 μM, was observed in these patient-derived 
LCLs within each treatment concentration. The median 
percent viability after 5ʹ-DFUR exposure in the patient 
derived LCLs, ranged from 60 percent (10 μM) to 34 
percent (160 μM). 
relationship between drug sensitivity measured 
in patient-derived lcls and that observed 
clinically
Clinical assessment and radiographic evaluation 
were performed on the majority of the patients at 12- week 
after initiation of capecitabine to assess their short term 
disease response. Response evaluation criteria in solid 
tumor (RECIST v1.1) criteria were applied and patient 
short term response was defined as complete response 
(CR), partial response (PR), stable disease (SD) or 
progressive disease (PD).  We performed regression 
analysis between the 12-week RECIST response 
categorization and patients’ 5ʹ-DFUR sensitivity obtained 
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in the LCL model (represented by Area under curve 
(AUC)). There is no significant association between patient 
RECIST-defined response at 12-week and response in their 
LCL model. There was, however, a trend showing patients 
with higher AUC in LCLs (representing resistance/less 
sensitivity to capecitabine) were more likely to have 
disease progression at 12-week (p = 0.086, Supplementary 
Figure 3). 
We also evaluated the relationship between 
ex vivo phenotype and PFS (represented by time to tumor 
progression). Among the 45 patients from whom we 
successfully established LCLs, 10 patients were lost to 
follow-up. Using AUC obtained from the remaining 35 
patient-derived LCLs, Cox regression and Kaplan-Meier 
analysis showed that patients with lower 5ʹ-DFUR AUC 
(higher sensitivity) had significantly better outcomes 
(Figure 1). These patients whose LCLs were more 
sensitive to 5ʹ-DFUR (defined as the lower halves of 
AUC distribution curve, Supplementary Figure 4), had 
a significantly longer PFS when compared to those 
patients whose LCLs were less sensitive to 5ʹ-DFUR 
(median PFS: 9-month vs. 6-month, log rank p = 0.017). 
In addition, after adjusting for other known important 
prognostic clinical variables such as presence of hepatic 
metastases and age, the positive correlation between ex 
vivo phenotype and clinical survival remained significant 
(p = 0.025). Overall, these data suggest that ex vivo 
capecitabine sensitivity obtained from patient-derived 
LCL models may predict patients’ clinical responses.
In vitro assessment of capecitabine sensitivity 
between matching breast cancer cell lines and 
lcls
Given the observed correlation between LCL 
sensitivity to 5ʹ-DFUR and patients’ PFS on capecitabine 
treatment, we hypothesized that at least a portion of the 
individual sensitivity to capecitabine is shared between 
germline tissue and tumor. To test this hypothesis, we 
took advantage of a collection of previously-established 
matching LCLs (germline) and breast cancer cell lines 
(tumor) [13]. We performed 5ʹ-DFUR sensitivity assays 
in both breast cancer cell lines and their matched LCLs 
derived from the same patient. Inter-individual differences 
in response to 5ʹ-DFUR were observed in both LCLs and 
breast cancer cell lines (Figure 2A). Using a Student T-test 
to evaluate sensitivity between the 2 cell models, we found 
that LCLs in general were more sensitive to 5ʹ-DFUR 
than breast cancer cell lines (Figure 2B, p = 0.0004). 
Interestingly, we found that 5ʹ-DFUR sensitivity in LCLs 
was highly correlated with the sensitivity in their matched 
breast cancer cell lines (Figure 2C) with the higher the 
LCL sensitivity, the higher the tumor sensitivity to the 
same drug treatment (Pearson correlation coefficient 
r = 0.86 and p = 0.0067). 
In addition, we hypothesized that for drugs that 
are designed to target tumor-specific mutations and 
amplifications, LCLs will not be a good model to predict 
their tumor response. To test this we treated a pair of LCLs 
table 1: Patient characteristics and clinical response 
Patient demographics (n = 53)*
     Median Age (range) 51 (36–79) yrs
     Ethnicity number %
White 38 71%
Black 9 17%
Asian 2 1%
Other/undisclosed 5 5%
clinical response **
     Short term response at 10–12 weeks
CR 1 (2.9%)
PR 7 (20%)
SD 12 (34.3%)
PD 10 (28.5%)
ND 5 (14.3%)
Number of patients with clinical response (percentages): Complete response (CR), Partial response (PR), Stable disease (SD), 
Progressive disease (PD), Not Disclosed (ND).  *45 out of the 53 patients included in the correlative study had successful 
establishment of their LCLs. ** upon assessment of clinical data, some of these patients who had LCLs were lost to 
follow-up.
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Figure 1: 5ʹ-DFUR sensitivity obtained from patient-derived LCLs can be used to predict breast cancer patients’ PFS. 
Kaplan-Meier curve represents PFS of stratified patients based on their LCL sensitivity to 5ʹ-DFUR. 18 patients who have greater than mean 
ex vivo 5ʹ-DFUR treatment AUC were compared to 17 patients who have lesser than mean ex vivo 5’-DFUR treatment AUC. Patients with 
lower AUC had a median 9 months PFS compared to those with higher AUC who only had a median of 6 months PFS (log rank p = 0.017).
Figure 2: Cellular sensitivity to 5ʹ-DFUR assessed in LCLs and their matched breast cancer cell lines. (A) Decreased 
cellular viability was observed in both breast cancer (BC) cell lines and their matched LCLs when treated with increasing concentrations 
of 5ʹ-DFUR for 72 hours. (b) Comparing cellular sensitivity to 5ʹ-DFUR in both the BC cell lines and their matched LCLs.  Student’s 
t-test p = 0.0004 shows a significant difference in cellular response between BC cell lines and their matched LCLs in  Area under the % 
viability curve (AUC) was calculated using trapezoidal rules. (c) AUC correlation between BC cell lines and their matched LCLs. Pearson 
correlation: r = 0.857 and p = 0.0067.
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along with their matching breast cancer cell lines with 
lapatinib, an epidermal growth factor receptor (EGFR) and 
HER2 tyrosine kinase inhibitor. As expected, HCC1954, 
a HER2-amplified breast cancer cell line, was highly 
sensitive to lapatinib compared to its matched HCC1954 
LCL line (P < 0.05, Figure 3A). Not surprisingly, in 
a second breast cancer cell line, HCC1937 (estrogen 
receptor (ER) and HER-2 negative), we observed very 
little sensitivity to lapatinib; and no sensitivity in the LCL 
derived from the same patient (Figure 3A). The minimal 
sensitivity of the cell line HCC1937 to lapatinib, an EGFR 
an HER2 inhibitor may be explained by its expression of 
EGFR [14, 15]. 
To further explore whether the observed response 
correlation between LCLs and cancer cell lines could be 
expanded to other cytotoxic drugs, we evaluated two other 
cytotoxic agents (daunorubicin and paclitaxel), and found 
that HCC1937 LCLs were more sensitive to daunorubicin 
and paclitaxel treatment than its matched HCC1937 breast 
cancer cell line (Figure 3B, 3C). HCC1954 LCL similarly 
showed more sensitivity to daunorubicin than its matched 
HCC1954 breast cancer cell line. Interestingly, under 
paclitaxel treatment, we observed similar high sensitivity 
in both HCC1954 breast cancer cell line and LCL from the 
same patient (HCC1954 LCL). This was consistent with 
the previous report that patients with a HER2-negative 
breast cancer benefitted from paclitaxel, regardless of 
estrogen-receptor status, but paclitaxel treatment did 
not benefit patients with HER2-negative cancers (like 
that of HCC1937) [16]. Overall, our data suggest that 
a germline model (like LCLs) may be used to predict 
tumor sensitivity to cytotoxic agents, while characterizing 
sensitivity to targeted therapy like lapatinib in LCLs is 
unlikely to be of use in predicting tumor sensitivity. 
dIscussIon
The International HapMap LCLs have been 
extensively used to identify genetic predictors of 
chemotherapy toxicity and sensitivity including 5ʹ-DFUR 
[9, 17, 18].  However, HapMap cells were derived from 
apparently healthy individuals. We therefore first sought 
to investigate whether we could establish LCLs from 
breast cancer patients. Our goal of establishing patient-
derived LCLs was successful (> 85% success rate). 
We showed that LCLs can be established from patient 
PBMCs isolated freshly or from whole blood preserved 
on ice and isolated with 48 hours. This supports the 
feasibility on incorporating LCL establishment in clinical 
trials, even those across multiple sites. In addition, we 
demonstrated that our method to develop LCLs resulted 
in highly reproducible data with minimal intra-individual 
Figure 3: Effects of other anti-tumor drugs on 2 pairs of matching BC cell lines and LCLs. HCC1954, HCC1937 and their 
matched LCLs were treated with (A) lapatinib (b) daunorubicin and (c) paclitaxel at their pharmacological concentrations. Percent cell 
viability was analyzed after 72 hours treatment with respective drugs. *p < 0.05.
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variability in response to 5ʹ-DFUR treatment. This allowed 
observation of inter-individual variability in response 
to 5ʹ-DFUR across different individuals. Given that 
laboratory-established LCLs can be cryopreserved (this 
will store donors’ genetic and gene expression information 
at the time of collection), we created a research resource 
that can be used for future experiments evaluating the 
genetic contribution to drug sensitivity. Furthermore, the 
drugs that may be evaluated in this model in the future are 
not limited to capecitabine. 
We next evaluated the role of patient-derived LCLs 
in predicting both short term and long term capecitabine 
treatment outcomes. Consistent with responses in previous 
studies, approximately 26 percent of patients in our study 
achieved CR+PR on single-agent capecitabine therapy [3]. 
We found no statistically significant correlation between 
capecitabine sensitivity derived from patient LCLs and 
their short term (10 to 12 weeks) response. However, 
there is a trend of positive correlation between them. This 
relationship is consistent with what was observed between 
ex vivo phenotype and long term response (represented by 
PFS). The lack of association may be due to the relatively 
small sample size of our correlative study, the short duration 
of treatment before response assessment, and/or decreased 
statistical power when evaluating categorical variable (ie, 
RECIST category) as compared to continuous variable (ie, 
PFS). Upon checking patients’ medical record, most patients 
remained on capecitabine treatment even after the end of the 
trial, as well as those who received dose reductions. 
Several clinical trials have shown that capecitabine 
significantly prolongs overall survival and PFS in the 
metastatic setting. Therefore, we also evaluated the 
correlation between the ex vivo 5ʹ-DFUR sensitivity 
phenotype to patients’ PFS. We found that patients with lower 
AUCs (higher ex vivo 5ʹ-DFUR sensitivity) in LCLs had 
a longer PFS than patients whose LCLs had higher AUCs. 
Despite the confounder of the variable dose reductions that 
patients received due to toxicities, studies have also shown 
that lower dosage of capecitabine does not affect overall 
efficacy of therapy [19, 20]. Previous studies have shown that 
age and hepatic metastasis are independent prognostic factors 
of capecitabine response [21]. When we adjusted for these 
variables, patient-derived LCL sensitivity data remained an 
independent, significant predictor of patient outcomes.
This significant correlation between patients’ 
ex vivo LCL and clinical outcome was further supported 
by an independent in vitro study of a collection of breast 
cancer cell lines with their matching LCLs. Our data seem 
to suggest that those shared germline elements between 
LCLs and tumor cells are important in cellular sensitivity 
to the cytotoxic agents.  
Overall, we demonstrated that establishing LCLs 
from breast cancer patients is feasible and potentially 
beneficial. If further validated, our data supports the 
utility of patient-derived LCLs as a predictive model for 
capecitabine treatment efficacy in breast cancer patients. 
We showed a shared response to cytotoxic agents among 
LCLs and breast cancer cells derived from the same 
individuals. Further development and optimization of 
patient-derived LCLs or other germline, blood-based 
ex vivo models might provide powerful tools in precision 
medicine to tailor patients’ therapies.
MAterIAls And Methods
Patients and clinical data collection 
We conducted our study as part of a larger clinical 
trial (TBCRC 015, NCT00977119) in which women with 
metastatic breast cancer were enrolled in a clinical trial 
examining genetic determinants of capecitabine toxicity. 
The dose of capecitabine prescribed was standardized in 
all patients as 2000 mg/m2/day. For our correlative study, 
a subset of patients enrolled from six sites (University of 
Chicago, University of Alabama, Vanderbilt University, 
The University of  Texas MD Anderson Cancer Center, 
University of Michigan and University of California - 
San Francisco) were included with the goal to evaluate 
the feasibility of creating ex vivo LCL models from breast 
cancer patients, and how these ex vivo drug sensitivity 
phenotypes related to patient capecitabine treatment 
response/toxicity phenotypes. The study was approved 
by the IRB of all participating institutions and informed 
consent was obtained from all study participants.
Both short term and long term clinical responses 
were collected. The short term response was measured 
at 10–12 weeks capecitabine treatment; while the long 
term response was assessed using PFS, which range 
from 6 weeks to 32 months. Clinical assessment and 
radiographic evaluation were performed on the majority 
of the patients at 12-week after initiation of capecitabine 
to assess their short term disease response. Response 
evaluation criteria in solid tumor (RECIST v1.1) criteria 
were applied and patient short term response was defined 
as complete response (CR), partial response (PR), stable 
disease (SD) or progressive disease (PD).  
Peripheral blood mononuclear cells isolation and 
lcl establishment
Ten milliliters of blood were drawn from each 
patient through venous puncture into BD Vacutainer® 
venous blood collection tubes (Lavender top), and inverted 
8–10 times. Blood samples were processed immediately 
(for all University of Chicago samples) or shipped on 
ice overnight to University of Chicago for processing. 
Peripheral blood mononuclear cells (PBMCs) were 
isolated using Accuspin™ System-Histopaque®-1077 
tubes as instructed by the manufacturer (Sigma-Aldrich®, 
St. Louis, MO) with some modifications. 
A previously-described Epstein-Barr virus (EBV) 
transformation protocol [22] was adapted to establish 
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LCLs from breast cancer patients enrolled into our study. 
When the cells reached a total viability of 80% the flasks 
were sub-cultured and further expanded to a total viable 
cell count of 3 × 107. Two independent LCL colonies were 
established from each patient’s peripheral blood sample. 
breast cancer cell lines and lcls derived from 
the same breast cancer donors
A collection of breast cancer cell lines (n = 8) 
and their paired EBV transformed LCLs (n = 8) were 
established previously [13] and obtained from the American 
Tissue Culture Collection (ATCC®) (Manassas, VA). Of 
the breast cancer cell lines, 2 were from patients who had 
human epidermal growth factor receptor 2 (HER2+) cancers 
(HCC1954 and HCC2218), 1 was from a patient with an 
estrogen receptor positive (ER+) tumor (HCC1428) and 5 
(HCC1937, HCC1143, HCC1187, HCC1599, HCC1395) 
were from patients who had triple negative breast cancers. 
Both the breast cancer cell lines and the matching LCLs 
were cultured according to ATCC protocol [13]. 
Ex vivo phenotyping
Patient-derived LCLs from the TBCRC trial and 
the ATCC purchased cell lines (both breast cancer cell 
lines and their matching LCLs from the same donors) 
were phenotyped for 5ʹ-DFUR sensitivity using Cell Titer 
Glo® (Promega, Madison WI) [9]. Because LCLs lack 
the expression of cytidine deaminase, an enzyme critical 
for the conversion of capecitabine to its active form, 
5ʹ-DFUR (10 μM, 20 μM, 40 μM, 80 μM and 160 μM), 
a major metabolite of capecitabine was used to evaluate 
capecitabine sensitivity in cell growth inhibition assays. 
Cells with > 85% viability were plated in triplicate at 
4000 cells per well in a 96-well plate (Corning, Corning 
NY). Cells were incubated with various concentrations of 
drug or vehicle control for 72 hours prior to the addition of 
Cell Titer Glo reagent in order to measure ATP levels in the 
culturing media. The area under curve (AUC) representing 
overall cellular sensitivity to the drug was calculated using 
the trapezoidal rule. For the matching breast cancer cell 
lines and LCLs, varying (pharmacologically achievable) 
concentrations of lapatinib (0.1–1 µM), daunorubicin 
(0.0125–0.2 µM) and paclitaxel (0.001–10 µM) were used 
to treat cells to confirm model validity. Each experiment 
was repeated at least 2 times in triplicate. 
statistics
Linear regression was performed between 
in vivo RECIST defined patients’ response at 12 weeks 
and response to 5ʹ-DFUR in patient-derived LCLs 
(represented by the area under the curve (AUC)). Kaplan 
Meier analysis on patients progression-free survival 
(PFS) was used to evaluate difference between LCLs 
that are more sensitive (n = 17 low AUC) or resistant 
(n = 18 high AUC) to 5ʹ-DFUR. Cox regression was used 
to adjust for multiple variables such as hepatic metastasis 
and age. Student‘s T-test was used to compare cellular 
response to 5ʹ-DFUR between patients’ LCLs and tumor 
cell lines. Pearson correlation was also used to evaluate 
correlation in 5ʹ-DFUR sensitivity between patient-
derived LCLs and their matched breast cancer cell lines.
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